Speciality Medicines Ltd
SPMLBSE
₹141.00▼ -0.80 (-0.56%)
Whole company worth₹124 Cr
Price for ₹1 of profit₹9.5
1-year range₹121 – ₹381
The short version
A fast-growing, profitable business — priced low for what it earns.
What Speciality Medicines does
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.
Worked out from Speciality Medicines's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Speciality Medicines is a micro-sized company in pharmaceuticals & biotechnology.
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.
- Whole company is worth
- ₹124 crore
- Shareholders
- 407 people
- Listed since
- 2026
A very small company by stock-market value — prices can swing hard and trading can be thin.
02Is it growing?
Sales have grown 48% a year for 3 years.
At that pace a business doubles in size roughly every 2 years. Profit grew even faster, at 87% a year — the business is keeping more of each rupee it brings in.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
Out of every ₹100 it sells, it keeps ₹17 as profit.
Here is where the money from Speciality Medicines's sales went in FY26, the latest full year it has reported.
₹72
₹8.8
₹17
- ₹72Making or buying what it sellsraw materials, stock, goods bought for resale
- ₹8.8Running the businessstaff, rent, marketing, power and everything else
- ₹1.8Interest on its loansthe cost of borrowed money
- ₹0.2Wear and tearmachines, stores and buildings losing value over time
- ₹17Profit it keepswhat is left for the company's owners
It also received a tax credit of ₹0.0 crore that year, which is why tax is missing from the bar.
On the money its owners have put in
It earns ₹18 a year on every ₹100 its owners have invested.
Bank FD ~₹6–7
₹18
₹0₹10₹20₹30₹40
That figure is called return on equity (ROE). Between ₹12 and ₹20 is a respectable return. For comparison, a bank fixed deposit pays roughly ₹6–7.
Does the profit turn into cash?
For every ₹100 of profit it reported, ₹-53 actually came in as cash.
Profit it reported₹23 Cr
Cash its business brought in−₹12 Cr
Over the last 3 years: ₹23 crore of profit but only −₹12 crore of cash. A wide gap like this is worth understanding before trusting the profit figure.
04Is the price high or low?
You pay ₹9.5 for every ₹1 of profit it makes in a year.
This is the P/E ratio: share price divided by a year's profit per share. A P/E of 9.5 means buyers are paying for about 9.5 years of today's profit up front.
The share price over the past year
It is 63% below its highest price of the past year and 16% above its lowest.
05Who owns it?
Its founders and parent group own 43 of every 100 shares — a large stake, though not a majority.
If the company were split into 100 equal shares, this is who would hold them. 407 people and institutions hold its shares.
As filed for the quarter ending 30 Sept 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
Three things going well, two things worth watching.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
- Sales have compounded at 48% a year.
- Earns ₹18 a year on every ₹100 of shareholders' money.
- Has almost no debt — it is not at the mercy of lenders.
Worth watching
- Thinly traded — only about ₹21 lakh of shares change hands a day, so buying or selling can move the price.
- The share price is 63% below its high of the past year.
07What happened lately?
Its latest quarter.
Jan–Mar 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹45 Cr
Profit
₹8.0 Cr
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Speciality Medicines?
This page describes Speciality Medicines using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Speciality Medicines Ltd (SPML): company summary
Speciality Medicines Ltd (SPML) is a micro-cap Healthcare company valued at ₹124 crore operating in Pharmaceuticals & Biotechnology on the NSE and BSE.
Speciality Medicines Ltd (SPML) is a micro-cap Healthcare company valued at ₹124 crore operating in Pharmaceuticals & Biotechnology on the NSE and BSE.
- Recent price move
- Speciality Medicines Ltd last traded at ₹141, modestly down 0.56% on the day.
- Financial performance
- Revenue has been growing strongly at 48.5% a year over three years; profit grew 86.8% a year, ahead of revenue — margins are expanding. Return on equity is 18.3%.
- Valuation multiples
- The stock trades at 9.5 times earnings, a discount to the Healthcare median of 32.0, 2.01 times book value.
- Things to watch
- The price sits 63% below its 52-week high.
Generated from DocStoX data. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Pharmaceuticals & Biotechnology
Explore Speciality Medicines Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Speciality Medicines Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedZydus Lifesciences LimitedApollo Hospitals Enterprise LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedMankind Pharma LimitedAurobindo Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Speciality Medicines Ltd with peers
Speciality Medicines Ltd vs Sun Pharmaceutical Industries LimitedSpeciality Medicines Ltd vs Divi's Laboratories LimitedSpeciality Medicines Ltd vs Torrent Pharmaceuticals LimitedSpeciality Medicines Ltd vs Zydus Lifesciences LimitedSpeciality Medicines Ltd vs Apollo Hospitals Enterprise LimitedSpeciality Medicines Ltd vs Laurus Labs Limited
Related tools & concepts
Value Speciality Medicines Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing